Literature DB >> 23259786

D2 lymphadenectomy can disseminate tumor cells into peritoneal cavity in patients with advanced gastric cancer.

X F Yu1, Z G Ren, Y W Xue, H T Song, Y Z Wei, C M Li.   

Abstract

We sought to determine the dissemination of gastric cancer cells before and after radical D2 surgery and to determine the effectiveness of EIPL in preventing post-operative peritoneal metastasis. 64 patients were recruited with advanced gastric cancer for our final analysis. Complete curative gastrectomy with D2 lymphadenectomy was performed on the 64 patients. Before surgery, peritoneal lavage fluid was collected for cytological analysis by cell smearing and immunohistochemistry to detect disseminated cancer cells (S1). Following tumor and lymph node resection, peritoneal lavage fluid was collected for cytological examination (S2). The patients were treated by extensive intra-operative peritoneal lavage (EIPL) with normal saline (n = 31) or distilled water (n = 33). The peritoneal lavage fluid was collected for cytological examination (S3). At S1 stage, 18 patients (28.1%) were positive for disseminated cancer cells in their abdominal fluid. After D2 lymphadenectomy, 34 patients (53.1%) had disseminated cancer cells in their abdominal fluid at stage S2, which indicated that the D2 lymphadenectomy caused in an additional 16 (16/46, 34.8%) patients positive for disseminated cancer cells. After EIPL with either normal saline or distilled water at the S3 stage), all the patients were negative for disseminated cancer cells in their abdominal fluid. A total of six patients died, and four patients had recurrencent cancer. These findings indicate that D2 lymphadenectomy can disseminate gastric cancer cells, and post-operative lavage of the abdominal cavity can eliminate cancer cell dissemination and decrease the risk of peritoneal metastasis.

Entities:  

Mesh:

Year:  2013        PMID: 23259786     DOI: 10.4149/neo_2013_023

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  7 in total

1.  The effect of extensive intraoperative peritoneal lavage therapy (EIPL) on stage III B + C and cytology-positive gastric cancer patients.

Authors:  Toshiro Masuda; Masafumi Kuramoto; Shinya Shimada; Satoshi Ikeshima; Kenichiro Yamamoto; Kenichi Nakamura; Shinich Yoshimatsu; Masayuki Urata; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2015-08-22       Impact factor: 3.402

Review 2.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ramakrishnan Ayloor Seshadri; Olivier Glehen
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

3.  Positive Peritoneal Lavage Cytology -Implications for Staging and Management of Gastric Cancer.

Authors:  Suman B Koganti; Satish Boddepalli; Muralidhar Nambada; Venu Madhav Thumma; Bheerappa Nagari; R A Sastry
Journal:  Indian J Surg Oncol       Date:  2016-05-06

4.  Does Extended Intraoperative Peritoneal Lavage Really Bring Benefit on Patients With Gastric Cancer? A Meta-Analysis of Published Clinical Trials.

Authors:  Wei Tao; Xiao-Yu Liu; Yu-Xi Cheng; Bing Kang; Hua Zhang; Chao Yuan; Bin Zhang; Dong Peng
Journal:  Front Oncol       Date:  2021-08-24       Impact factor: 6.244

Review 5.  The benefits of surgery plus extensive intraoperative peritoneal lavage (EIPL) for patients with gastric cancer compared with surgery alone: a systematic review and meta-analysis.

Authors:  Shujun Li; Laiyou Li; Bibo Tan; Jiajia Wang; Shan Xue
Journal:  Updates Surg       Date:  2021-06-25

Review 6.  Free intraperitoneal tumor cells and outcome in gastric cancer patients: a systematic review and meta-analysis.

Authors:  Mathieu Pecqueux; Johannes Fritzmann; Mariam Adamu; Kristian Thorlund; Christoph Kahlert; Christoph Reißfelder; Jürgen Weitz; Nuh N Rahbari
Journal:  Oncotarget       Date:  2015-11-03

Review 7.  Risk Assessment and Preventive Treatment for Peritoneal Recurrence Following Radical Resection for Gastric Cancer.

Authors:  Lin Xiang; Shuai Jin; Peng Zheng; Ewetse Paul Maswikiti; Yang Yu; Lei Gao; Jing Zhang; Ying Zhang; Hao Chen
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.